Keith Goldan joined OptiNose in January 2017 as Chief Financial Officer.  He brings to the company more than 25 years of executive financial and operational leadership in biopharmaceutical and medical technology companies including CFO roles at private and public life sciences companies from early through commercial stage. Mr. Goldan most recently served as Senior Vice President and Chief Financial Officer at Fibrocell, a publicly-held cell and gene therapy company, and of NuPathe, where he helped direct the sale of the specialty pharmaceutical company to Teva in 2014.  In these roles, Mr. Goldan led finance, IT, HR and corporate development teams and successfully raised capital though an IPO as well as multiple follow-on equity, rights, private placement and debt offerings. Mr. Goldan’s experience also includes CFO roles at PuriCore (now Realm Therapeutics) and Biosyn as well as of roles with ViroPharma and KPMG. Keith holds a BS (cum laude) in finance from the Robert H. Smith School of Business at the University of Maryland and an MBA from the Wharton School of Business at the University of Pennsylvania.

Chief Financial Officer,executive financial and operational leadership